Ruti Aga Banned for Six Years: A Family Member Forged the Prescription, and a Defensible Case Became Career Death

The Athletics Integrity Unit (AIU) announced on Thursday that Ruti Aga, the Ethiopian marathon runner, has been banned for six years. The sanction is the sum of two separate violations: two years for the presence of a prohibited substance — methylprednisolone — in her sample in-competition, and four years for tampering after she submitted a forged medical prescription during the investigation.

Aga, 32, had been provisionally suspended since 10 September, and that same date anchors the start of the six-year period. The statement does not spell out the end date, but the arithmetic is unambiguous. In practical terms, the 2028 Olympic cycle is now entirely closed to her.

This is not a routine doping case. Three layers make it unusual. First, the substance involved is not an anabolic steroid but a glucocorticoid, and that distinction is legally decisive. Second, the decisive offence was not the medication but the forged paperwork produced to defend it. Third, the prescription was not written by a doctor but by a family member with no medical registration, invoking a clinic that did not exist.

The arithmetic: two plus four

The numbers in the AIU statement are informative in themselves. Two years for the presence violation is the standard outcome for a Specified Substance where intent to cheat is not established. Four years for tampering is the fixed sanction under the World Anti-Doping Code, with no discretion applied.

Added together, they produce six years. The implication is that the panel rejected the No Significant Fault or Negligence mitigation that would have pulled the presence sanction below two years. Forged documentation is itself circumstantial evidence of concealment intent, yet the panel did not use it to aggravate the presence sanction — it treated it as a separate, fully culpable offence. That is technically coherent, but it produces the odd result of the same course of conduct being weighed on two separate scales.

Backdating the ban to 10 September is not a concession. Time already served under provisional suspension counts against the total, so the athlete gains nothing in real terms. It is procedural bookkeeping, not leniency.

What methylprednisolone actually is

Early reporting described methylprednisolone as a prohibited steroid and stated that WADA classifies it as performance enhancing. That is imprecise. Methylprednisolone is a glucocorticoid, listed under class S9 of the WADA Prohibited List, not an anabolic steroid under S1.

The distinction matters because it is the legal hinge of the case. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection administered out-of-competition is entirely lawful. It becomes a violation only if residues are present in a sample taken in-competition.

That means the case turned not on whether she took the drug, but on route of administration and timing. Testing windows in road racing open at 23:59 the day before the race, so an injection given days earlier can still be caught. With genuine medical records and a clear route-and-timing explanation, a defence was available.

The media error matters because the word steroid conjures a different and much heavier picture in public perception. Anabolic steroids and glucocorticoids should not be weighed on the same scale. The basis of Aga's sanction was never proof of performance benefit; it was that residues were present on race day and that an attempt was made to conceal their origin.

The sequence of events

According to the available information, Aga won a half marathon in China in March. A sample collected at that race returned an adverse finding for methylprednisolone. The statement does not specify the year, though the references to a provisional suspension from 10 September and a statement issued on Thursday strongly imply the current year.

The source gives no finishing time, no splits, no field strength and no technical context. Any assessment of the performance itself would therefore be speculation. The only firm fact is that she won — which implies a World Athletics Label-tier road race with a credible elite field and in-competition testing. Without that, no AIU test would exist.

Aga's explanation was a knee injury. Medically, that is entirely plausible. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. The problem was never that the story was unbelievable. It was that a genuine treatment would have been evidenced with genuine records.

Three independent verification failures

The investigation did not uncover a single documentary slip. It failed at three separate verification stages. The clinic named on the prescription did not exist. The person who wrote it was a family member, not a registered physician. And that person claimed to have used an old prescription pad from a former workplace — a claim the clinic publicly disowned.

Any one of those links holding would have changed the case. All three failing together made it effectively impossible to argue honest error.

It is worth being precise here: fabricating a prescription is a separate offence from the presence violation, and it carries the heavier sanction. The very thing Aga reached for to protect herself became her largest liability. Had she produced no document and simply argued injury and injection timing, her defence would have been weaker but alive.

Career accounting: Tokyo 2026 survives, the March race does not

Aga's competitive record is beyond dispute. She won the 2026 Tokyo Marathon, a World Marathon Major, and has three second-place finishes at World Marathon Majors. Public records place her best in the low 2:18 range, set with a second place at the 2026 Berlin Marathon, though that figure cannot be independently confirmed within the scope of this report.

The key legal point is that the violation is anchored to the March race. Absent a finding of earlier use, results before that date are not automatically annulled, so the 2026 Tokyo title survives on the record.

Her result and prize money from the March race, however, will almost certainly be voided, even though the statement does not say so explicitly. Standard AIU practice is automatic disqualification of the competition at which the sample was collected, along with forfeiture of ranking points accrued thereafter.

The result is a split legacy. The Tokyo title and the Major podiums remain the record of a genuinely elite marathoner. The six-year ban makes her commercially radioactive in a sport where distance-running sponsorship is already thin.

Age and the prospect of return

Aga is 32. When the ban expires she will be nearly 38. That is not an age at which athletes return at the top of the women's marathon, particularly in Ethiopia, where the depth absorbs a single absence almost invisibly.

And age is not the only barrier. A 38-year-old with a doping record is, in practical terms, unselectable for a national team regardless of when the ban ends. Technically the sanction is time-limited; functionally it is a lifetime ban.

The injury profile points the same way. The knee problem does not read as an acute event. The attempt to manufacture a paper trail suggests a long-running pattern of informal treatment rather than a single lapse. Nobody fabricates an old prescription for a one-off mistake.

The real root cause: a medical-governance failure

What stands out most is the absence, anywhere in the account, of a credentialed team physician. The doctor was a family member with no medical registration. That is not a filing error; it is the signature of an athlete operating without formal medical support.

There is also no visible TUE infrastructure. A properly managed athlete with a documented knee injection would either hold or apply for a Therapeutic Use Exemption, or observe WADA's route-specific washout guidance. Neither appears to have happened, and the choice of forgery over defence confirms it.

A third point is often missed: the four-year tampering sanction arises from an interview, not from a document alone. It is the product of statements made under questioning. Language and translation conditions in AIU interviews with East African athletes have repeatedly been a point of contention. How much that mattered here is not clear from the public statement, but it cannot be dismissed.

There is a broader economic driver. Injured marathoners face strong pressure to mask pain in order to protect appearance-fee income. Glucocorticoids are the cheapest and most available tool for that. The surrounding medical network is informal. The forgery is downstream of an untreated governance gap.

China's label circuit: where appearance fees and testing collide

Aga's post-2026 racing pattern is clear — selective Major appearances, with Asian label races in between. For a 2:18–2:20 marathoner this is a classic model: high appearance fees, low race count, low risk.

China's half-marathon circuit is a lucrative, low-risk income tier for East African marathoners between Majors. It is also now one of the AIU's highest-yield testing grounds. The appearance-fee economy and the testing economy are colliding in the same races, and results from this tier will increasingly carry integrity risk.

Ethiopian depth: no competitive impact

Ethiopia's position in the women's marathon is extraordinary — world-record class at the top, with depth so deep that a 2:18 performer is not automatically selectable. Kenya matches that depth, with different strengths: Ethiopia leads at the very top, Kenya converts better in championship races.

Against that backdrop, Aga's removal does not alter national selection arithmetic by any measurable margin. Her three Major second places were commercial-tier results, not championship medals. The competitive landscape is untouched.

The real subject is governance. The cluster of AIU road-running cases emerging from East Africa repeatedly involves tampering charges, which suggests the enforcement frontier has shifted from detection to document verification. Aga's case is not an outlier; it belongs to a recognisable family where an initial substance violation is compounded by a fabricated explanation.

The rules framework and the road not taken

The case ran under the World Athletics Anti-Doping Rules, enforced by the AIU and applying the WADA Code (2026) and the Prohibited List. Both charges were established: presence of an S9 glucocorticoid in-competition, and tampering.

One dimension sits outside AIU jurisdiction — potential criminal exposure for document forgery under national law. It is not raised in the statement, but it cannot be ruled out entirely.

The instructive counterfactual is this: with genuine medical records and a credible route-and-timing explanation, the presence charge could have been argued at the no-fault or no-significant-fault end, potentially attracting a reprimand or a substantially reduced period, with no tampering charge at all. The best case, a TUE-consistent treatment plan with correct washout timing, would have produced no case whatsoever.

Appeal: available but weak

Aga retains a theoretical route to the Court of Arbitration for Sport, typically within about 21 days of the reasoned decision. But the tampering finding is document-based, built on three independent verification failures, and is very hard to overturn. The presence finding rests on the sample itself, leaving limited room as well.

The larger question: proportionality

A six-year ban for a glucocorticoid with no proven endurance benefit is a striking outcome, and it will be cited from both directions. On one side it will be read as evidence of AIU rigour — that the unit pursues documentary fraud as aggressively as it pursues major substances. On the other, it will be read as evidence of disproportionate enforcement against African road runners. Both arguments will have supporters.

One thing is clear. Of the six years, four exist because Aga forged a document no clinic ever issued. Without that prescription, the sanction would likely have sat near two years, and at 34 a theoretical route back would have remained open. That route is now closed as well.

Conclusion

Ruti Aga's case is a marker of how anti-doping enforcement is changing. The first question used to be what an athlete took. Now the question also includes how she tried to explain it. Here the story of the medicine became secondary, and the story of the paperwork became decisive.

Aga was an exceptional marathoner — the 2026 Tokyo title and three Major podiums are testimony to that. She was caught inside a system where knee pain was treated by a family member rather than a registered physician, where no TUE framework existed, and where the pressure of scrutiny produced paperwork instead of the truth.

A six-year ban at 32 is not merely a sanction; it is the end of a career. But the case is not only about one runner's future. It is about how thin medical governance remains in the East African road-running ecosystem, and how an untreated injury, an informal doctor and an old prescription pad — three small things — can permanently attach a world-class athlete's name to a doping record.

The AIU did its job. The open question is who carries the responsibility that should have come earlier: a real doctor, a real record and correct advice on the day the knee first hurt.